A painful lesson from the COVID-19 pandemic: the need for broad-spectrum, host-directed antivirals
Abstract While the COVID-19 pandemic has spurred intense research and collaborative discovery worldwide, the development of a safe, effective, and targeted antiviral from the ground up is time intensive. Therefore, most antiviral discovery efforts are focused on the re-purposing of clinical stage or approved drugs. While emerging data on drugs undergoing COVID-19 repurpose are intriguing, there is an undeniable need to develop broad-spectrum antivirals to prevent future viral pandemics of unknown origin. The ideal drug to curtail rapid viral spread would be a broad-acting agent with activity against a wide range of viruses. Such a drug would work by modulating host-proteins that are often shared by multiple virus families thereby enabling preemptive drug development and therefore rapid deployment at the onset of an outbreak. Targeting host-pathways and cellular proteins that are hijacked by viruses can potentially offer broad-spectrum targets for the development of future antiviral drugs. Such host-directed antivirals are also likely to offer a higher barrier to the development and selection of drug resistant mutations. Given that most approved antivirals do not target host-proteins, we reinforce the need for the development of such antivirals that can be used in pre- and post-exposure populations..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
---|---|
Enthalten in: |
Journal of translational medicine - 18(2020), 1 vom: 15. Okt. |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Chitalia, Vipul C. [VerfasserIn] |
---|
Links: |
Volltext [kostenfrei] |
---|
doi: |
10.1186/s12967-020-02476-9 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
SPR041353803 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | SPR041353803 | ||
003 | DE-627 | ||
005 | 20230519220007.0 | ||
007 | cr uuu---uuuuu | ||
008 | 201102s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1186/s12967-020-02476-9 |2 doi | |
035 | |a (DE-627)SPR041353803 | ||
035 | |a (SPR)s12967-020-02476-9-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |q ASE |
100 | 1 | |a Chitalia, Vipul C. |e verfasserin |4 aut | |
245 | 1 | 2 | |a A painful lesson from the COVID-19 pandemic: the need for broad-spectrum, host-directed antivirals |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Abstract While the COVID-19 pandemic has spurred intense research and collaborative discovery worldwide, the development of a safe, effective, and targeted antiviral from the ground up is time intensive. Therefore, most antiviral discovery efforts are focused on the re-purposing of clinical stage or approved drugs. While emerging data on drugs undergoing COVID-19 repurpose are intriguing, there is an undeniable need to develop broad-spectrum antivirals to prevent future viral pandemics of unknown origin. The ideal drug to curtail rapid viral spread would be a broad-acting agent with activity against a wide range of viruses. Such a drug would work by modulating host-proteins that are often shared by multiple virus families thereby enabling preemptive drug development and therefore rapid deployment at the onset of an outbreak. Targeting host-pathways and cellular proteins that are hijacked by viruses can potentially offer broad-spectrum targets for the development of future antiviral drugs. Such host-directed antivirals are also likely to offer a higher barrier to the development and selection of drug resistant mutations. Given that most approved antivirals do not target host-proteins, we reinforce the need for the development of such antivirals that can be used in pre- and post-exposure populations. | ||
650 | 4 | |a COVID-19 |7 (dpeaa)DE-He213 | |
650 | 4 | |a Broad-spectrum antivirals |7 (dpeaa)DE-He213 | |
650 | 4 | |a Mechanism of action (MOA) |7 (dpeaa)DE-He213 | |
650 | 4 | |a Pandemics |7 (dpeaa)DE-He213 | |
650 | 4 | |a Drug discovery and development |7 (dpeaa)DE-He213 | |
650 | 4 | |a SARS-CoV-2 |7 (dpeaa)DE-He213 | |
650 | 4 | |a Host-directed antivirals |7 (dpeaa)DE-He213 | |
650 | 4 | |a Antiviral drug design |7 (dpeaa)DE-He213 | |
650 | 4 | |a Coronavirus (CoV) |7 (dpeaa)DE-He213 | |
650 | 4 | |a Drug design strategies |7 (dpeaa)DE-He213 | |
650 | 4 | |a Prophylactic antiviral therapy |7 (dpeaa)DE-He213 | |
700 | 1 | |a Munawar, Ali H. |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Journal of translational medicine |d London : BioMed Central, 2003 |g 18(2020), 1 vom: 15. Okt. |w (DE-627)SPR028930886 |w (DE-600)2118570-0 |x 1479-5876 |7 nnns |
773 | 1 | 8 | |g volume:18 |g year:2020 |g number:1 |g day:15 |g month:10 |
856 | 4 | 0 | |u https://dx.doi.org/10.1186/s12967-020-02476-9 |z kostenfrei |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_SPRINGER | ||
912 | |a SSG-OLC-PHA | ||
951 | |a AR | ||
952 | |d 18 |j 2020 |e 1 |b 15 |c 10 |